| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSK |
| Uniprot No | P43235 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 115-329aa |
| 氨基酸序列 | APDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM |
| 预测分子量 | 25.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CTSK(组织蛋白酶K)重组蛋白研究的参考文献及其摘要概括：
1. **《Expression, purification, and characterization of recombinant human cathepsin K》**
- 作者：McGrath ME, et al.
- 摘要：该研究报道了利用昆虫细胞表达系统成功表达并纯化人源CTSK重组蛋白，并通过晶体学分析揭示了其三维结构，阐明了其与胶原降解相关的活性位点特征。
2. **《Functional analysis of cathepsin K mutations in pycnodysostosis patients》**
- 作者：Hou WS, et al.
- 摘要：通过构建突变型CTSK重组蛋白，研究揭示了遗传病致密性骨发育不全症患者中CTSK基因突变对其酶活性和底物结合能力的影响，为疾病机制提供了分子层面的解释。
3. **《Development of a high-yield Escherichia coli system for recombinant cathepsin K production》**
- 作者：Li Z, et al.
- 摘要：优化了大肠杆菌表达体系，实现CTSK重组蛋白的高效可溶性表达，并通过体外活性实验证实重组蛋白具有与天然酶相似的胶原降解活性，为大规模制备提供了可行方案。
4. **《Inhibitor screening platform using recombinant cathepsin K for osteoporosis drug discovery》**
- 作者：Runger TM, et al.
- 摘要：基于重组CTSK蛋白构建了高通量抑制剂筛选模型，鉴定出多个新型小分子抑制剂，并验证其在骨质疏松症动物模型中抑制骨吸收的效果。
以上研究涵盖了CTSK重组蛋白的结构解析、疾病关联、表达优化及药物开发应用，均为该领域的关键文献。
Cathepsin K (CTSK), a lysosomal cysteine protease primarily expressed in osteoclasts, plays a pivotal role in bone remodeling by degrading collagen and other extracellular matrix components during bone resorption. Its unique substrate specificity and high enzymatic activity make it a critical regulator of skeletal homeostasis. Dysregulation of CTSK is implicated in pathologies such as osteoporosis, osteoarthritis, and bone metastasis, positioning it as a therapeutic target for these conditions.
Recombinant CTSK protein is produced using genetic engineering techniques, where the CTSK gene is cloned into expression vectors (e.g., bacterial, insect, or mammalian systems) to enable large-scale, purified protein production. This approach ensures consistent quality and activity, overcoming limitations of native protein isolation from tissues. The recombinant form retains the enzymatic properties of native CTSK, including pH-dependent proteolytic activity and inhibition by endogenous cystatins or synthetic inhibitors.
In research, recombinant CTSK is utilized to study bone metabolism mechanisms, screen inhibitory compounds for drug development, and model disease progression. For instance, CTSK inhibitors (e.g., odanacatib) have been explored clinically for osteoporosis treatment, though balancing efficacy and side effects remains challenging. Beyond skeletal disorders, CTSK's involvement in vascular calcification, cancer invasion, and fibrosis has expanded its relevance in cardiovascular and oncology research.
Additionally, recombinant CTSK serves as an antigen for antibody production or diagnostic assays, aiding biomarker studies. Its application in 3D disease models and tissue engineering highlights its versatility in translational research. However, challenges persist in optimizing stability, activity, and delivery methods for therapeutic use. Ongoing studies aim to elucidate structure-function relationships and tissue-specific roles, further cementing CTSK's importance in biomedical science.
×
